MYOS RENS Technology (MYOS) Getting Somewhat Favorable Press Coverage, Report Shows

News coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MYOS RENS Technology earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media headlines about the company an impact score of 43.7617704383955 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

MYOS RENS Technology (NASDAQ MYOS) remained flat at $1.35 on Tuesday. 49,234 shares of the stock traded hands. The stock’s market cap is $7.89 million. The stock has a 50-day moving average price of $1.78 and a 200-day moving average price of $2.43. MYOS RENS Technology has a 12-month low of $1.02 and a 12-month high of $6.98.

Separately, ValuEngine raised MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th.

WARNING: “[[title]]” was first reported by [[site]] and is owned by of [[site]]. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at [[permalink]].

MYOS RENS Technology Company Profile

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.